EMA Lapsed: Clopidogrel Teva Generics B.V. (clopidogrel (as hydrochloride)) — Teva Pharma B.V.

View source ↗

Summary

EMA has lapsed the marketing authorization for Clopidogrel Teva Generics B.V. (clopidogrel as hydrochloride).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Myocardial Infarction
• Peripheral Vascular Diseases
• Stroke

Drugs mentioned

• Clopidogrel Teva Generics B.V. (clopidogrel (as hydrochloride))

Snippet

Status: Lapsed. Therapeutic area: Peripheral Vascular Diseases;Acute Coronary Syndrome;Myocardial Infarction;Stroke. MAH: Teva Pharma B.V.. Decision date: 05/11/2013